New hope for tough lung cancer: experimental drug targets resistant tumors
NCT ID NCT05450965
First seen Jan 05, 2026 · Last updated May 10, 2026 · Updated 14 times
Summary
This study tests a drug called onvansertib in people with small cell lung cancer whose cancer did not respond to or came back after chemotherapy. The drug blocks a protein that cancer cells need to repair themselves. About 37 participants will take the drug to see if it shrinks tumors and how safe it is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UPMC Hillman Cancer Center
ACTIVE_NOT_RECRUITINGPittsburgh, Pennsylvania, 15232, United States
-
University of Maryland Greenebaum Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21201, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.